Search results
Showing 1 to 10 of 10 results for elranatamab
Evidence-based recommendations on elranatamab (Elrexfio) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults.
In development Reference number: GID-TA11956 Expected publication date: 28 January 2027
In development Reference number: GID-TA10979 Expected publication date: TBC
In development Reference number: GID-TA11052 Expected publication date: 17 February 2027
Elranatamab for treating relapsed or refractory multiple myeloma after 2 treatments [ID6464]
Awaiting development Reference number: GID-TA11661 Expected publication date: TBC
Managed access allows people to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.
Evidence-based recommendations on talquetamab (Talvey) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults.
Evidence-based recommendations on belantamab mafodotin (Blenrep) with pomalidomide and dexamethasone for previously treated multiple myeloma in adults.
Two new treatment options for incurable blood cancer assessed
We’ve recommended 2 new treatments for multiple myeloma, an incurable blood cancer that affects bone marrow, in draft guidance issued for public consultation.
Hundreds of people with multiple myeloma could receive a new, targeted treatment recommended for use within the Cancer Drugs Fund today (Tuesday, 29 October).